Medicare's Price Controls Could Raise Prices
· news
The Unintended Consequences of Medicare’s Price Controls
The Inflation Reduction Act, signed into law by President Biden in 2019, aimed to control pharmaceutical costs by letting Medicare set drug prices. Proponents claimed this would save taxpayers billions over the next decade. However, a new study suggests that this approach may ultimately raise average lifetime prices for certain medications.
University of Chicago economist Tomas Philipson and his colleagues conducted research showing that Medicare’s price controls could lead to an 19% increase in average lifetime prices for the first 25 medicines selected for price-setting. This outcome seems counterintuitive, but it’s a predictable result when considering competition dynamics in the pharmaceutical market.
The development of generic and biosimilar medications relies on substantial returns after brand-name medicines lose their exclusivity. Medicare’s price controls suppress branded revenues before this point, effectively disincentivizing companies from investing in competing products. With fewer potential competitors entering the market, prices are likely to remain high for years to come.
The pharmaceutical industry balances temporary market exclusivity with vigorous generic competition. The Inflation Reduction Act risks upsetting this balance by prioritizing short-term savings over long-term market dynamics. Policymakers may inadvertently create an environment that stifles innovation and drives up costs in the long run.
Philipson’s study relies on empirical evidence from real-world markets, demonstrating how government-set prices can reduce net prices for branded medicines but lead to higher post-exclusivity prices due to reduced competition. Similar patterns have emerged in other industries where artificially low prices or subsidies disrupt market dynamics and lead to unintended consequences.
The stakes are high for taxpayers and patients who rely on affordable access to life-saving medications. Policymakers must recognize the potential long-term costs of short-sighted policy decisions as they implement the IRA’s price controls. The true test of this law will be its ability to balance affordability with innovation – a delicate balance already showing signs of strain.
The pharmaceutical industry is often seen as complex and opaque, but the dynamics at play are surprisingly straightforward: companies invest when potential returns justify costs and risk. Policymakers must ask whether artificially suppressing branded revenues before exclusivity ends aligns with this fundamental principle.
If the IRA’s price controls disrupt the balance between innovation and competition, they will fail to achieve their intended goal of controlling pharmaceutical costs. Policymakers must consider the long-term consequences of their actions, as a system that prioritizes short-term gains over sustainability may ultimately drive up costs for consumers who can least afford them.
As the IRA’s price controls take effect, monitoring their impact on the competitive market will be crucial to understanding their true cost. Policymakers must also consider what these controls do to the very fabric of competition that keeps prices in check – a balance essential to keeping drug prices low for decades to come.
Reader Views
- RJReporter J. Avery · staff reporter
The Inflation Reduction Act's price controls on Medicare may have been well-intentioned, but they're also a classic example of government overreach. By artificially lowering drug prices for certain medications, the law inadvertently discourages pharmaceutical companies from developing cheaper alternatives. This is a fundamental flaw in the policy: it prioritizes short-term cost savings over long-term market dynamics and innovation. Policymakers would do well to consider the ripple effects on industry competition and the eventual cost of medication development.
- EKEditor K. Wells · editor
The Inflation Reduction Act's price controls were supposed to bring down pharmaceutical costs, but what if they actually end up driving prices higher in the long run? The study by Tomas Philipson highlights a crucial dynamic: the investment potential of generic and biosimilar medications relies on the revenue generated by branded drugs. By suppressing those revenues through price controls, we risk stifling innovation and creating an environment where companies have little incentive to develop competing products, leading to artificially inflated prices. Policymakers should consider this unintended consequence before further regulating the pharmaceutical market.
- CSCorrespondent S. Tan · field correspondent
The study's finding that Medicare's price controls could lead to higher average lifetime prices for certain medications is a stark reminder of the unintended consequences of government intervention in free markets. A critical consideration is the potential impact on small biotech firms, which often rely on short-term revenue from branded medicines to fund research and development of new treatments. By suppressing these revenues, Medicare's price controls could effectively strangle innovation at its earliest stages, perpetuating a cycle of high costs and limited access to life-saving medications.